Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Alzheimer’s disease could be slowed by boosting a certain protein in the brain, researchers say
Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The University of Cincinnati researchers and an Alzheimer's Association expert weigh in.
Study shows Alzheimer’s drugs may boost protein, not just lower amyloid
Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, the drugs boost levels of a healthy form of amyloid beta (Aβ42) protein in the brain,
Boosting brain protein levels may slow decline from Alzheimer's
A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the slowing of cognitive impairment at least as well as the reduction in amyloid plaques.
Alzheimer's Decline May Be Slowed by Protein Boost
"Aβ42 is a protein that defends our brain from a variety of toxic and infectious exposures," Espay said. "In the process of reacting, it transforms into amyloid plaques. Amyloid plaques is made of clumped up Aβ42. Once in amyloid, Aβ42 no longer works (the plaques can be viewed as a tombstone of Aβ42)."
Alzheimer's Drugs May Work in Whole New Way, Study Finds
Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It's thought the drugs curb Alzheimer's by reducing levels of toxic amyloid protein plaques in the brain.
Boosting brain protein levels may slow Alzheimer’s progression
A new study published in the journal Brain reveals that increasing levels of a key brain protein might help slow cognitive decline in Alzheimer’s patients. This finding challenges the long-held belief that reducing amyloid plaques is the best way to treat the disease.
Study finds Alzheimer's drugs might boost healthy protein in brain
Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.
McKnight's Long-Term Care News
21h
Study: Amyloid-beta, tau buildup affect brain activity before Alzheimer’s shows up
A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...
1d
New study challenges amyloid-beta theory on cause for Alzheimer's disease
New research suggests that the lessening of amyloid-beta in the brain is behind cognitive decline in Alzheimer's and boosting ...
6d
Amyloid Plaques May Not Cause Alzheimer’s: New Research Challenges Decades-Old Theories
A study shows that rising levels of brain protein Aβ42, not the reduction of amyloid plaques, better explains the cognitive ...
13d
Study uncovers critical biomarker differences, advocates for more inclusive Alzheimer's diagnostics
The Emory Goizueta Brain Health Institute (GBHI) has prioritized involving African American volunteers in its research, ...
Endocrinology Advisor
6d
Caffeine Intake Might Protect Against Alzheimer Disease, Mild Cognitive Impairment
Caffeine and Alzheimer disease risk appear to be linked, as lower caffeine intake is associated with Alzheimer disease biomarkers.
16d
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback